S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Germany urged to cap heat in offices this winter to save gas
This Could Be THE Watershed Moment of Our Financial Lives (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Germany urged to cap heat in offices this winter to save gas
This Could Be THE Watershed Moment of Our Financial Lives (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Germany urged to cap heat in offices this winter to save gas
This Could Be THE Watershed Moment of Our Financial Lives (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Germany urged to cap heat in offices this winter to save gas
This Could Be THE Watershed Moment of Our Financial Lives (Ad)pixel
NYSE:BHC

Bausch Health Companies - BHC Stock Forecast, Price & News

$6.01
-0.19 (-3.06%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$5.99
$6.30
50-Day Range
$4.58
$9.21
52-Week Range
$4.00
$29.59
Volume
6.59 million shs
Average Volume
10.95 million shs
Market Capitalization
$2.17 billion
P/E Ratio
50.09
Dividend Yield
N/A
Price Target
$10.10

Bausch Health Companies MarketRank™ Forecast

Analyst Rating
Hold
2.20 Rating Score
Upside/​Downside
68.1% Upside
$10.10 Price Target
Short Interest
Healthy
3.74% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.96
Upright™ Environmental Score
News Sentiment
-0.28mentions of Bausch Health Companies in the last 14 days
Based on 12 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
16.72%
From $3.41 to $3.98 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.12 out of 5 stars

Medical Sector

13th out of 1,135 stocks

Pharmaceutical Preparations Industry

2nd out of 557 stocks

BHC stock logo

About Bausch Health Companies (NYSE:BHC) Stock

Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Bausch Health Companies Trading Down 3.1 %

BHC Stock traded down $0.19 during trading on Friday, hitting $6.01. 6,588,147 shares of the company traded hands, compared to its average volume of 10,953,922. The company has a debt-to-equity ratio of 85.63, a quick ratio of 1.00 and a current ratio of 1.08. The company has a 50-day moving average of $7.68 and a 200-day moving average of $15.82. The firm has a market capitalization of $2.17 billion, a PE ratio of 50.09, a P/E/G ratio of 0.09 and a beta of 1.35. Bausch Health Companies has a 1 year low of $4.00 and a 1 year high of $29.59.

Bausch Health Companies (NYSE:BHC - Get Rating) last issued its earnings results on Tuesday, May 10th. The company reported $0.72 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.03 by ($0.31). Bausch Health Companies had a negative return on equity of 9,431.58% and a net margin of 0.52%. The firm had revenue of $1.92 billion during the quarter, compared to the consensus estimate of $2.06 billion. Analysts predict that Bausch Health Companies will post 3.41 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on BHC shares. JPMorgan Chase & Co. downgraded shares of Bausch Health Companies from an "overweight" rating to a "neutral" rating in a research report on Thursday, July 28th. Royal Bank of Canada cut their price target on Bausch Health Companies from $5.00 to $4.50 and set a "sector perform" rating for the company in a research note on Wednesday. StockNews.com cut Bausch Health Companies from a "buy" rating to a "hold" rating in a report on Wednesday, May 11th. BMO Capital Markets reduced their price objective on shares of Bausch Health Companies from $26.00 to $15.00 in a research note on Wednesday, May 11th. Finally, Truist Financial lowered shares of Bausch Health Companies from a "buy" rating to a "hold" rating in a research report on Thursday, July 28th. Five research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Hold" and an average price target of $10.10.

Receive BHC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bausch Health Companies and its competitors with MarketBeat's FREE daily newsletter.

BHC Stock News Headlines

27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate. pixel
Bausch Health Companies (NYSE:BHC) Shares Gap Down to $5.84
Our Most Important Forecast in 50 Years Tectonic changes are on the way.
We take great pride in our long history of accurate forecasts for investors. From our early warning of the stock market crash in 1987 to just last year when we predicted Russia's invasion of Ukraine and the massive spike in resource prices that followed it. And now, we are releasing our most important forecast of all. A convergence we believe will upend nearly everything about the way we live, save and invest.
Bausch Health Companies (NYSE:BHC) Sees Large Volume Increase
Expert Ratings for Bausch Health Companies
Bausch + Lomb Provides Leadership Update
See More Headlines
Receive BHC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bausch Health Companies and its competitors with MarketBeat's FREE daily newsletter.

BHC Company Calendar

Last Earnings
8/02/2021
Today
8/14/2022
Next Earnings (Estimated)
11/01/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
19,600
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.10
High Stock Price Forecast
$15.00
Low Stock Price Forecast
$4.50
Forecasted Upside/Downside
+68.1%
Consensus Rating
Hold
Rating Score (0-4)
2.20
Research Coverage
5 Analysts

Profitability

Net Income
$-948,000,000.00
Pretax Margin
0.32%

Debt

Sales & Book Value

Annual Sales
$8.43 billion
Cash Flow
$8.97 per share
Book Value
$0.70 per share

Miscellaneous

Free Float
311,354,000
Market Cap
$2.17 billion
Optionable
Optionable
Beta
1.35

Key Executives

  • Mr. Thomas J. Appio (Age 60)
    CEO & Director
    Comp: $2.9M
  • Mr. Thomas G. Vadaketh (Age 59)
    Exec. VP & CFO
  • Mr. Mirza Dautbegovic
    Sr. VP & COO
  • Mr. John S. Barresi (Age 49)
    Sr. VP, Controller & Chief Accounting Officer
  • Dr. Robert F. Butz
    VP of Medical & Scientific Affairs
  • Mr. Arthur J. Shannon
    Sr. VP and Head of Investor Relations & Global Communications
  • Ms. Seana Carson (Age 50)
    Exec. VP & Gen. Counsel
  • Ms. Kathleen Fitzpatrick
    Sr. VP & Chief HR Officer
  • Dr. Tage Ramakrishna M.D. (Age 48)
    Chief Medical Officer and Pres of R&D
  • Mr. Jeff Hartness
    Sr. VP of Market Access, Commercial Operations & Gov. Affairs













BHC Stock - Frequently Asked Questions

Should I buy or sell Bausch Health Companies stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bausch Health Companies in the last twelve months. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" BHC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BHC, but not buy additional shares or sell existing shares.
View BHC analyst ratings
or view top-rated stocks.

What is Bausch Health Companies' stock price forecast for 2022?

5 brokers have issued 1 year price targets for Bausch Health Companies' stock. Their BHC share price forecasts range from $4.50 to $15.00. On average, they predict the company's stock price to reach $10.10 in the next year. This suggests a possible upside of 68.1% from the stock's current price.
View analysts price targets for BHC
or view top-rated stocks among Wall Street analysts.

How have BHC shares performed in 2022?

Bausch Health Companies' stock was trading at $27.61 at the start of the year. Since then, BHC stock has decreased by 78.2% and is now trading at $6.01.
View the best growth stocks for 2022 here
.

Are investors shorting Bausch Health Companies?

Bausch Health Companies saw a decline in short interest in July. As of July 31st, there was short interest totaling 13,050,000 shares, a decline of 20.1% from the July 15th total of 16,330,000 shares. Based on an average daily trading volume, of 8,570,000 shares, the days-to-cover ratio is presently 1.5 days. Currently, 3.7% of the company's shares are sold short.
View Bausch Health Companies' Short Interest
.

When is Bausch Health Companies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our BHC earnings forecast
.

How were Bausch Health Companies' earnings last quarter?

Bausch Health Companies Inc. (NYSE:BHC) issued its earnings results on Monday, August, 2nd. The company reported $0.97 EPS for the quarter, beating analysts' consensus estimates of $0.95 by $0.02. The company had revenue of $2.10 billion for the quarter, compared to analyst estimates of $2.12 billion. Bausch Health Companies had a net margin of 0.52% and a negative trailing twelve-month return on equity of 9,431.58%.

What guidance has Bausch Health Companies issued on next quarter's earnings?

Bausch Health Companies issued an update on its FY 2022 earnings guidance on Tuesday, August, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $8.05 billion-$8.22 billion, compared to the consensus revenue estimate of $8.34 billion.

What is Joseph C. Papa's approval rating as Bausch Health Companies' CEO?

43 employees have rated Bausch Health Companies Chief Executive Officer Joseph C. Papa on Glassdoor.com. Joseph C. Papa has an approval rating of 97% among the company's employees. This puts Joseph C. Papa in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Bausch Health Companies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bausch Health Companies investors own include Gilead Sciences (GILD), Micron Technology (MU), Constellation Software (CSU), Intact Financial (IFC), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Advanced Micro Devices (AMD) and Bank of America (BAC).

What is Bausch Health Companies' stock symbol?

Bausch Health Companies trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHC."

Who are Bausch Health Companies' major shareholders?

Bausch Health Companies' stock is owned by many different institutional and retail investors. Top institutional shareholders include Segantii Capital Management Ltd (1.58%), Fiera Capital Corp (0.95%), Bank of Montreal Can (0.68%), Bank of Nova Scotia (0.64%), Private Management Group Inc. (0.46%) and Letko Brosseau & Associates Inc. (0.46%). Insiders that own company stock include Amy B Wechsler, Christina Ackermann, Eschenbach Andrew C Von, Holdings LP Valueact, John Paulson, Joseph C Papa, Joseph F Gordon, Mark C Mckenna, Robert Spurr, Russell Barrans, Sam Eldessouky, Schutter Richard U De, Steven D Miller and William D Humphries.
View institutional ownership trends
.

How do I buy shares of Bausch Health Companies?

Shares of BHC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bausch Health Companies' stock price today?

One share of BHC stock can currently be purchased for approximately $6.01.

How much money does Bausch Health Companies make?

Bausch Health Companies (NYSE:BHC) has a market capitalization of $2.17 billion and generates $8.43 billion in revenue each year. The company earns $-948,000,000.00 in net income (profit) each year or $0.12 on an earnings per share basis.

How many employees does Bausch Health Companies have?

The company employs 19,600 workers across the globe.

How can I contact Bausch Health Companies?

Bausch Health Companies' mailing address is 2150 ST. ELZEAR BLVD. WEST, LAVAL A8, H7L 4A8. The official website for the company is www.bauschhealth.com. The company can be reached via phone at (514) 744-6792, via email at ir@bauschhealth.com, or via fax at 514-744-6272.

This page (NYSE:BHC) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.